Metrics to compare | 688221 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688221PeersSector | |
|---|---|---|---|---|
P/E Ratio | 2,117.3x | 13.0x | −0.4x | |
PEG Ratio | 21.25 | 0.16 | 0.00 | |
Price/Book | 6.6x | 5.1x | 2.6x | |
Price / LTM Sales | 18.7x | 19.1x | 3.1x | |
Upside (Analyst Target) | - | 37.7% | 48.6% | |
Fair Value Upside | Unlock | 1.8% | 5.8% | Unlock |
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company’s pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.